Galderma announced topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s… read more.
Pelthos Therapeutics Inc. announced it has acquired Xeglyze (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million. Xeglyze is a pediculicide indicated for the topical… read more.
Johnson & Johnson announced that the European Commission (EC) has extended the marketing authorisation for Tremfya (guselkumab) as a subcutaneous treatment to treat moderate to severe plaque psoriasis… read more.
Abeona Therapeutics Inc. announced the first patient treatment with FDA-approved Zevaskyn (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive… read more.
The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response… read more.
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumours, while reducing side effects. This is reported by researchers… read more.
Treating malignant melanoma with lower doses of approved immunotherapy appears to result in improved results, while also reducing side effects. Investigators from the Karolinska Institutet in Stockholm, Sweden… read more.
Some blood pressure medications can make the skin extra prone to sunburn. A registry study from Lund University in Sweden shows a possible increased risk of basal cell… read more.
Adult acne is more common than often assumed. According to research from the University of Oulu, around 31 per cent of 35-year-old Finnish women have acne on the… read more.
Incyte announced new data from the Phase IIIb TRuE-AD4 study evaluating the efficacy and safety of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had… read more.
NICE (UK): Delgocitinib can be used, within its marketing authorisation, as an option to treat moderate to severe chronic hand eczema in adults when topical corticosteroids have not… read more.
Pelthos Therapeutics Inc. announced it has acquired the U.S. marketing rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. and Ferrer Internacional S.A. (the Xepi is a non-fluorinated… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
